Johnson & Johnson (JNJ)
Johnson & Johnson Announces a Major Acquisition. Can It Turn the Stock's Fortunes Around?
Johnson & Johnson (JNJ -0.47%) has a diverse healthcare business, and investors often look to it as a safe dividend stock to invest in for the long term. One area where it has been lacking, however, is growth.
Did Johnson & Johnson Just Give Investors 23 Billion Reasons to Buy Its Stock?
Johnson & Johnson (JNJ -0.47%) didn't have an exceptional 2024; in fact, it was one of the worst-performing stocks on the vaunted, 30-company Dow Jones Industrial Average that year.
US government could seek over $1 billion from J&J for cancer treatment costs
The U.S. Department of Health & Human Services may seek over $1 billion from Johnson & Johnson as reimbursement for federal health agencies' payments of medical costs for patients who allege that the company's baby powder and other talc products caused them to develop cancer, a government attorney said Friday.
Why Johnson & Johnson's Strong Buy Rating Is Justified (Rating Upgrade)
On January 22, Johnson & Johnson released financial results for the fourth quarter of 2024, which beat my expectations again. So, sales of its oncology franchise reached $5.5 billion, an increase of 19% compared to the fourth quarter of 2023. Moreover, Johnson & Johnson expects its operational sales to grow by 2% to 3% in 2025, while its adjusted diluted EPS will be between $10.50 and $10.70, implying single-digit percentage growth.
Here's Why Johnson & Johnson (JNJ) is a Strong Value Stock
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
3 Stocks Upgraded by Bank of America – Here's Why They're Bullish
The new trading year is getting started, and investors might be looking to make this one either as strong as 2024 was or even stronger yet. To do this, it is always preferred to start on a strong note, meaning that the first quarter of the year has to bring about a net outperformance to give portfolios enough momentum and room to pursue some of the more aggressive growth projects later in the year.
Spravato sales surged highlights commercial viability of psychedelics, analysts believe
The latest quarterly sales figures for Johnson & Johnson (NYSE:JNJ)'s esketamine nasal spray support the notion that psychedelics can become commercially viable for mental health, analysts at Jefferies believe. Fourth quarter Spravato sales grew by 5% quarter-over-quarter to $297 million driven by increased physician and patient demand.
How to Play J&J Stock After Q4 Beat & Soft 2025 Sales Guidance
Those who own JNJ stock may stay invested for some time as the company looks optimistic about a better performance in 2025.
Here is What to Know Beyond Why Johnson & Johnson (JNJ) is a Trending Stock
Johnson & Johnson (JNJ) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Why Traders Are Buying the Dip on Johnson & Johnson Stock
It is no secret that the defensive names in the stock market today, the ones not known for their hot price action or wild return potential, have been the lackluster segment of the financial markets lately. This is because the center of attention has been taken by the technology sector and some of the darling names in that space for all of 2023 and 2024.
What's Next For JNJ Stock After An Upbeat Q4?
Johnson & Johnson (NYSE: JNJ) recently reported its Q4 results, with revenues and earnings exceeding the street estimates. The company reported revenue of $22.5 billion and adjusted earnings of $2.04 per share, compared to the consensus estimates of $22.4 billion and $2.02, respectively.
Johnson & Johnson's MedTech Momentum Expected To Rebound In 2025 Despite Current Hurdles: Analyst
On Wednesday, Johnson & Johnson JNJ reported a fourth-quarter adjusted EPS of $2.04, down 10.9% year over year, beating the consensus of $2.01.
